Rheumatology

Click on each therapeutic area to learn more.

Rheumatoid arthritis (RA)

Although the anomalous response of the immune system is not understood, it has been shown that excessive or prolonged IL-1 signaling promotes joint inflammation and damage. Key factors that contribute to the progression of the disease include genetics, environment, and sex hormones.

RA publications

The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.

A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial of Anakinra (Kineret), a Recombinant Interleukin-1 Receptor Antagonist, in Patients With Rheumatoid Arthritis Treated With Background Methotrexate
Annals of the Rheumatic Diseases, April 2004
View source
Treatment of Rheumatoid Arthritis With Recombinant Human Interleukin-1 Receptor Antagonist
Arthritis & Rheumatism, December 1998
View source

RA resources

Review the recommended resources for additional clinical insights.

The Role of IL-1 in Autoinflammation

View the infographic to learn more about the local and systemic effects of IL-1.

Diagnosis of IL-1–Driven Diseases

View the presentation to learn more about clinical signs and symptoms, testing, and biomarkers.

Uncontrolled gout (UG)

Gout is the most common form of inflammatory arthritis. UG is a type of gout that persists despite conventional treatments. The condition is caused by a buildup of serum uric acid (sUA), which can result in tophi and/or frequent, prolonged gout flares. In the United States, approximately 2% of people with gout have UG.

UG publications

The publications on this page pertain to an investigational Sobi product and are based on publicly available data. This product is not approved by the FDA or any other regulatory body and therefore safety and efficacy have not been established. This information is not intended to be a comprehensive overview of all publications in this disease area.

Patient Experience With Uncontrolled Gout and Its Impact on Health-Related Quality of Life: Literature Review and Qualitative Analysis
Rheumatology and Therapy, August 2024
View source
The COMPARE Head-to-Head, Randomized Controlled Trial of SEL-212 (Pegadricase Plus Rapamycin-Containing Nanoparticle, ImmTOR™) Versus Pegloticase for Refractory Gout
Rheumatology, July 2023
View source
Phase 2 Dose-Finding Study in Patients With Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined With Tolerogenic Nanoparticles (SEL-110)
Rheumatology and Therapy, April 2023
View source
Tolerogenic Nanoparticles Mitigate the Formation of Anti-Drug Antibodies Against Pegylated Uricase in Patients With Hyperuricemia
Nature Communications, January 2022
View source

UG resources

Review the recommended resources for additional clinical insights.

uncontrolled gout
Uncontrolled Gout and Metabolic Disorders

View the presentation to learn more about UG progression and comorbidities.

Connect with an MSL

Sobi Medical Science Liaisons are highly trained, scientific and clinical subject matter experts who can provide in-depth answers to your disease and treatment questions.

Contact us